Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2008, the Company had one marketed product: ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available for prescription in the United States for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in adults and children aged 12 and older. Regeneron also has six clinical development programs, including three late-stage clinical programs. Its late-stage programs are aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group; VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and ARCALYST, which is being developed for the treatment of gout.